Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last --
Change Today 0.00 / 0.00%
Volume 0.0
4974 On Other Exchanges
Symbol
Exchange
4974 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

takara bio inc (4974) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TAKARA BIO INC (4974)

Related News

No related news articles were found.

takara bio inc (4974) Related Businessweek News

No Related Businessweek News Found

takara bio inc (4974) Details

Takara Bio Inc. operates as a biotechnology company in Japan and internationally. It operates in three segments: Genetic Engineering Research, Gene Medicine, and AgriBio. The company develops research reagents and scientific instruments, such as restriction enzymes, PCR reagents, antibodies, cell culture media and gas-permeable bags, real-time PCR equipment, mass spectrometry systems, etc. It also provides research and contract manufacturing services comprising genome analysis, DNA chip analysis, IPS cell contract production services, cell processing and preparation, vector production, safety testing, technical support services for cancer immunotherapy, etc. In addition, the company engages in the development of various gene therapies, including HF10 anti-cancer therapy that is in Phase II clinical trials targeting malignant melanoma; TCR gene therapy, which targets esophageal cancer using next-generation retroviral vectors that is in Phase I clinical trials; and MazF gene therapy, which is in Phase I clinical trial in the United States for patients infected with the human immunodeficiency virus. Further, it researches on functional properties derived from traditional Japanese food ingredients; and provides functional food ingredients as raw materials for foods, drinks, and cosmetics. Additionally, the company provides functional foods, such as Fucoidan from Gagome kombu, Isosamidin from a herbs, Chalcone from Ashitaba, Agaro-oligosaccharide from Agar, Yamsgenin from the lesser yam, and Terpene from a mushroom. It also cultivates, produces, and markets various mushroom types, such as Honshimeji, Hatakeshimeji, and Bunashimeji, as well as licenses mushroom cultivation technology. The company was founded in 2002 and is headquartered in Otsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

1,236 Employees
Last Reported Date: 06/26/15
Founded in 2002

takara bio inc (4974) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

takara bio inc (4974) Key Developments

Takara Bio Inc. to Report Q1, 2016 Results on Jul 29, 2015

Takara Bio Inc. announced that they will report Q1, 2016 results on Jul 29, 2015

Takara Bio Inc., Annual General Meeting, Jun 23, 2015

Takara Bio Inc., Annual General Meeting, Jun 23, 2015.

Takara Bio Group Announces Earnings Results for the Year Ended March 31, 2015; Provides Earnings Guidance for the Fiscal Year Ending March 31, 2016

Takara Bio Group announced earnings results for the year ended March 31, 2015. For the year, the company reported sales of JPY 25,969 million against JPY 23,905 million a year ago. Operating income was JPY 2,302 million against JPY 1,954 million a year ago. For the fiscal year ending March 31, 2016, the company expects to record a year-on-year increase in net sales of 9.0%, to JPY 28,300 million, due to increased sales mostly of research reagents and contract research. In terms of income, gross profit is forecasted at JPY 15,761 million (up 14.0% year on year) to efforts to expand high-profitability research reagents and restructure the mushroom business in addition to an increase in net sales. Operating income is projected to increase 2.1%, to JPY 2,350 million, as SG&A expenses are expected to rise due primarily to higher R&D expenses and personnel expenses. Capital expenditures were JPY 4,762 million against JPY 5,538 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4974:JP ¥1,309.00 JPY +3.00

4974 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $10.75 USD -0.11
Luminex Corp $20.21 USD +2.90
Thermo Fisher Scientific Inc $137.77 USD -0.67
View Industry Companies
 

Industry Analysis

4974

Industry Average

Valuation 4974 Industry Range
Price/Earnings 100.0x
Price/Sales 5.8x
Price/Book 2.6x
Price/Cash Flow 170.9x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKARA BIO INC, please visit www.takara-bio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.